Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Illumina and Mayo ClinicTo Develop Molecular Diagnostic Tests

By HospiMedica staff writers
Posted on 19 Jan 2007
Illumina, Inc. More...
(San Diego, CA, USA) and Mayo Clinic (Rochester, MI, USA) have signed a diagnostic collaborative agreement to enable the co-development of molecular diagnostic tests for the study of complex diseases.

Illumina will contribute its VeraCode technology and development expertise for the BeadArray and BeadXpress instrument platforms. Mayo Clinic will bring broad knowledge in clinical practice and patient outcome management, along with proficiency in establishing clinical utility of new diagnostic technologies. In addition, Mayo's ability to discover and validate biomarkers offers the potential for both parties to implement important new clinical tests.

Terms of the agreement enable the implementation of new clinical tests within Mayo's clinical practice and Mayo Medical Laboratories. Additionally, Illumina will manufacture and market tests worldwide on Illumina's BeadArray and upcoming BeadXpress Reader.

Illumina's patented BeadArray technology achieves a level of array miniaturization that allows for a new scale of experimentation. An array is a collection of miniaturized test sites arranged on a surface that permits many tests, or assays, to be performed in parallel. By arranging analytic devices into a multi-sample array of arrays format, one can process in parallel thousands to millions of assays, a throughput significantly beyond the capability of any technology known to us.

Illumina's VeraCode technology leverages the power of digital holographic codes to provide a robust detection method for multiplexed assays requiring high precision, accuracy and speed. This technology, combined with Illumina's BeadXpress Reader, supports the rapid detection and analysis of a wide range of assays with industry leading multiplexing capability.

The department of laboratory medicine and pathology at Mayo Clinic maintains an active diagnostic test development program. These activities also incorporate technologies from collaborations with diagnostic and biotechnology companies. Mayo utilizes these proven diagnostic technologies in the care of its patients and offers them to more than 5,000 health care institutions around the world through Mayo Medical Laboratories (MML). Revenue from MML testing is used to support medical education and research at Mayo Clinic.



Related Links:
Illumina
Mayo Clinic

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.